Special Issue

Adverse Drug Reactions and Gender Differences

Message from the Guest Editors

In the era of personalized and precision medicine, gender differences continue to be a "grey zone" that requires better definition, especially in terms of drug response and tolerability. Several studies suggest that gender and sex differences could result in different drug tolerability in terms of adverse drug reaction (ADR) frequency and seriousness.

Advances in pharmacology are essential to understand the gender differences associated with pharmacological treatments. Although the data available regarding the impact of gender on the safety profiles of medicinal products shows a prevalence of ADR occurrence amongst females over males, gender-specific pharmacovigilance activities must be undertaken in order to reduce the risks associated with the use of medicinal products and to conduct a risk/benefit assessment in greater detail to elucidate the differences between men and women in terms of pharmacokinetics and pharmacodynamics. In this Special Issue, experts are invited to submit clinical trial, experimental, original, and review articles that contribute to improving the understanding of the different drug safety profiles related to gender differences.

Guest Editors

Dr. Concetta Rafaniello

Department of Experimental Medicine, University of Campania "L. Vanvitelli", Via Santa Maria di Costantinopoli 16, 80138 Naples, Italy

Dr. Annalisa Capuano

Department of Experimental Medicine, University of Campania "L. Vanvitelli", Via Santa Maria di Costantinopoli 16, 80138 Naples, Italy

Deadline for manuscript submissions

closed (31 December 2021)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/59820

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

